AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Eleusis Presents New Research on the Anti-Inflammatory Potential of Serotonin 2A Receptor Agonists at the 2019 International Society for Research on Psychedelics

October 23, 2019 GMT

LONDON & NEW YORK--(BUSINESS WIRE)--Oct 23, 2019--

Eleusis, a clinical stage life science company established to develop the therapeutic potential of serotonin 2A receptor (5-HT2A) agonists, also known as psychedelics, today announced new research presented at the inaugural 2019 International Society for Research on Psychedelics (ISRP) conference held October 18-20, in New Orleans, U.S. In both oral platform presentations and posters, Eleusis data demonstrated preclinical efficacy of topically administered serotonin 2A receptor agonists in viral, allergen, and antigen induced ocular inflammation, via translational models of herpes keratitis, allergic conjunctivitis, uveitis, and diabetic macular edema. In addition, Eleusis sponsored researchers also presented on the anti-inflammatory potential of serotonin 2A agonists in translational models of asthma, cardiovascular disease, and for the first time, revealed new findings that suggest a potent anti-fibrotic effect of serotonin 2A agonists in vitro, consistent with previously disclosed effects against pulmonary fibrosis.

“We are excited to present these new findings at the inaugural ISRP meeting, and believe they expand the scientific community’s appreciation for the full potential of psychedelics as subperceptual medicines,” said Shlomi Raz, Chairman and Founder of Eleusis. “The findings presented further demonstrate the anti-inflammatory capacity of serotonin 5-HT2A receptor agonists, and specifically, their potential to treat ocular inflammation and prevent retinal degeneration.”

Eleusis Presentation Details

Oral Presentations

Session Title: Anti-Inflammatory Effects of Psychedelics

Poster Session

About Eleusis Ltd.

Eleusis is a privately-held, clinical stage life science company, established to unlock the transformative potential of psychoactive drugs, through the mitigation and management of psychoactivity. The company is developing an innovative platform of drug discovery and digital health technologies enabling the advance of therapeutics targeting urgent unmet needs across a broad spectrum of inflammatory and stress related diseases.

Follow Eleusis on LinkedIn

View source version on businesswire.com:https://www.businesswire.com/news/home/20191023005205/en/

CONTACT: Investors:

Courtney Turiano

Stern Investor Relations, Inc.

212-362-1200

courtney.turiano@sternir.comMedia:

Carol Guaccero

media@eleusisltd.com

301-606-4722

KEYWORD: NEW YORK EUROPE UNITED STATES UNITED KINGDOM NORTH AMERICA

INDUSTRY KEYWORD: RESEARCH DIABETES CLINICAL TRIALS BIOTECHNOLOGY ALTERNATIVE MEDICINE HEALTH PHARMACEUTICAL OTHER SCIENCE SCIENCE

SOURCE: Eleusis

Copyright Business Wire 2019.

PUB: 10/23/2019 09:00 AM/DISC: 10/23/2019 09:01 AM

http://www.businesswire.com/news/home/20191023005205/en